KYMR Skyrockets 82.4% in a Year: More Upside Potential in 2026?

Key Takeaways KYMR surged after KT-621 showed deep STAT6 degradation and strong EASI and pruritus reductions.KT-621 cut multiple type 2 biomarkers and was mostly safe, supporting its potential as a once-daily therapy.FDA Fast Track and ongoing phase IIb AD and asthma studies position KT-621 for broader late-stage development.Kymera Therapeutics, Inc. (KYMR) has put up a stupendous performance over the past year. Shares of this clinical-stage biotechnology company have surged 82.4% over the said time frame c ...